 |
|
|
|
| Selected Reading |
 AAP. The child with suspected anthrax exposure or infection. American Academy of Pediatrics, Dec 20, 2001 [Full-text Web document]
Abboud N, Casadevall A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 2008 Jul;15(7):1115-23 [Abstract]
Abboud N, Casadevall A. The immunogenicity of Bacillus anthracis protective antigen domains and the efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 2008 (published online May 14) [Abstract]
Abergel RJ, Wilson MK, Arceneaux JEL, et al. Anthrax pathogen evades the mammalian immune system through stealth siderophore production. Proc Natl Acad Sci 2006 (published online Nov 28) [Abstract]
Abramova FA, Grinberg LM, Yampolskaya OV. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci 1993;90:2291-4
ACOG. Advisory to physicians on anthrax treatment of pregnant women [Full text]
Agrawal A, Lingappa J, Leppa SH, et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. (Letter) Nature 2003 Jul 17;424(6946):329-34
Akoachere M, Squires RC, Nour AM, et al. Identification of an in vivo inhibitor of Bacillus anthracis spore germination. J Biol Chem 2007 Apr 20;282(16):12112-8 [Abstract]
Albrecht MT, Li H, Williamson ED, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007 Nov;75(11):5425-33 [Abstract]
Alexander JJ, Colangelo PM, Cooper CK, et al. Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations. Pediatr Infect Dis 2008 (published online Oct 1) [Abstract]
Allen JS, Skowera A, Rubin GJ, et al. Long-lasting T cell responses to biological warfare vaccines in human vaccinees. Clin Infect Dis 2006 Jul 1;43(1):1-7 [Abstract]
Amadi S, Dutz W, Kohout E, et al. Human anthrax in Iran: Report of 300 cases and review of the literature. Tropenmed Parasitol 1974;25(1):96-104
Ambrose PG, Forrest A, Craig WA, et al. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimcrob Agents Chemother 2007 Dec;51(12):4351-5 [Abstract]
Anaraki S, Addiman S, Nixon G, et al. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Eurosurveill 2008 Dec 18;13(51):pii=19076 [Full text]
Artenstein AW, Opal SM, Cristofaro P, et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J Infect Dis 2004 Nov 1;190(9):1655-60 [Abstract]
Aulinger BA, Roehrl MH, Mekalanos JJ, et al. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 2005 Jun 1;73(6):3408-14 [Abstract]
Baccam P, Boechler M. Public health response to an anthrax attack: an evaluation of vaccination policy options. Biosecur Bioterror 2007 Apr;5(1):26-34 [Abstract]
Backer MV, Patel V, Jehning BT, et al. Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother 2007 Jan;51(1):245-51 [Abstract]
Baggett HC, Rhodes J, Fridkin SK, et al. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Clin Infect Dis 2005 Oct 1;41(7):991-7 [Abstract]
Barakat LA, Quentzel, HL, Jernigan JA, et al, for the Anthrax Bioterrorism Investigation Team. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002;2287:863-7 [Full text]
Barrow EW, Dreier J, Reinelt S, et al. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis. Antimicrob Agents Chemother 2007 Dec;51(12):4447-52 [Abstract]
Beecher DJ. Forensic application of microbiological culture analysis to identify mail intentionally contaminated with Bacillus anthracis spores. Appl Environ Microbiol 2006 Aug;72(8):5304-10 [Abstract]
Begier EM, Barrett NL, Mshar PA, et al. Gram-positive surveillance for early anthrax detection. Emerg Infect Dis 2005 Sep;11(9) [Full text]
Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 2002;8(2):222-5 [Full text]
Belongia EA, Kieke B, Lynfield R, et al. Demand for prophylaxis after anthrax outbreaks. Emerg Infect Dis 2005 Jan;11(1):42-7 [Full text]
Bergman NH, Anderson EC, Swenson EE, et al. Transcriptional profiling of Bacillus anthracis during infection of host macrophages. Infect Immun 2007 Jul;75(7):3434-44 [Abstract]
Bielinska AU, Janczak KW, Landers JJ, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007 Aug;75(8):4020-9 [Abstract]
Bienek DR, Biagnini RE, Charlton DG, et al. Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the US-licensed anthrax vaccine. Clin Vaccine Immunol 2008 Apr;15(4):644-9 [Abstract]
Bienek DR, Chang CK, Cohen ME. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine. Vaccine 2007 Aug 10;25(32):5978-84 [Abstract]
BioPort Corporation. Anthrax vaccine adsorbed (Biothrax) [Web site]
Bischof TS, Hahn BL, Sohnle PG. Characteristics of spore germination in a mouse model of cutaneous anthrax. J Infect Dis 2007 Mar 15;195(6):888-94 [Abstract]
Black DG, Taylor TM, Kerr HJ, et al. Decontamination of fluid milk containing Bacillus spores using commercial household products. J Food Prot 2008 Mar;71(3):473-8 [Abstract]
Blank S, Moskin LC, Zucker JR. An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001. Emerg Infect Dis 2003 Jun;9(6):615-22 [Full text]
Borio L, Frank D, Mani V, et al Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 2001:286(20):2554-9 [Full text]
Borio LL, Gronvall GK. Anthrax countermeasures: current status and future needs. Biosec Bioterr 2005 Jun;3(2) [Full text]
Bozue J, Moody KL, Cote CK, et al. Bacillus anthracis spores of the bclA mutant exhibit increased adherence to epithelial cells, fibroblasts, and endothelial cells but not to macrophages. Infect Immun 2007 Sep;75(9):4498-505 [Abstract]
Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:432-445
Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001 Nov 8;414(6860):225-9 [Abstract]
Bravata DM, Holty JEC, Wang E, et al. Inhalational, gastrointestinal, and cutaneous anthrax in children. Arch Ped Adolesc Med 2007 Sep;161(9):896-905 [Abstract]
Bravata DM, Wang E, Holty JE, et al. Pediatric anthrax: implications for bioterrorism preparedness. Prepared by Stanford University-UCSF Evidence-based Practice Center for AHRQ (Agency for Healthcare Research and Quality). Aug 2006 [Full text]
Brookmeyer R, Blades N, Hugh-Jones M, et al. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001 Jun;2(2):233-47 [Abstract]
Brookmeyer R, Blades N. Prevention of inhalational anthrax in the US outbreak. Science 2002 Mar 8;295(5561):1861
Brookmeyer R, Johnson E, Bollinger R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci 2003 Aug 19;100(17):10129-32 [Full text]
Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature 2004 Dec 16;432(7019):901-4 [First paragraph]
Brooks KL, Dauenhauer SA. The anthrax team: a novel teaching approach to increase anthrax and bioterrorism awareness. Am J Infect Control 2003 May;31(3):176-7 [Abstract]
Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 2002;70(2):661-4 [Full text]
Buckeridge DL, Owens DK, Paul Switzer P, et al. Evaluating detection of an inhalational anthrax outbreak. Emerg Infect Dis 2006 Dec;12(12) (published online Nov 6) [Full text]
Bush LM, Abrams BH, Beall A, et al. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001;345(22):1607-10 [Full text]
Butler JC, Cohen ML, Friedman CR, et al. Collaboration between public health and law enforcement: new paradigms and partnerships for bioterrosim planning and response. Emerg Infect Dis 2002 Oct;8(10):1152-6 [Full text]
Cataldi A, Mock M, Bentancor L. Characterization of Bacillus anthracis strains used for vaccination. J Appl Microbiol 2000 Apr;88(4):648-54 [Abstract]
Cavallo JD, Ramisse F, Girardet M, et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002 Jul;46(7):2307-9 [Full text]
CDC. Additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR 2001;50(50):1142 [Full text]
CDC. Adverse events associated with anthrax prophylaxis among postal employees?New Jersey, New York City, and the District of Columbia metropolitan area, 2001. MMWR 2001:50(47):1051-4 [Full text]
CDC. Anthrax Q & A: Anthrax and Animal Hides [Full text]
CDC. Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR 1999;48(4)69-74 [Full text]
CDC. Comprehensive procedures for collecting environmental samples for culturing Bacillus anthracis. Apr 2002 [Full text]
CDC. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR 2001;50(44):984-6 [Full text]
CDC. Cross-contamination of clinical specimens with Bacillus anthracis during a laboratory proficiency test--Idaho, 2006. MMWR 2008 Sep 12;57(36);993-5 [Full text]
CDC. Cutaneous anthrax associated with drum making using goat hides from West Africa--Connecticut, 2007. MMWR 2008 Jun 13;57(23):628-31 [Full text]
CDC. Cutaneous anthrax in a laboratory worker - Texas, 2002. MMWR 2002 Jun 7;51(22)482 [Full text]
CDC. Evaluation of Bacillus anthracis contamination inside the Brentwood mail processing and distribution center?District of Columbia, October 2001. MMWR 2001;50(50):1129-33 [Full text]
CDC. Follow-up of deaths among US Postal Service workers potentially exposed to Bacillus anthracis: District of Columbia, 2001-2002. MMWR 2003 Oct 3;52(39):937-8 [Full text]
CDC. Hand-held immunoassays for detection of Bacillus anthracis. Oct 18, 2001 [Full text]
CDC. Inadvertent laboratory exposure to Bacillus anthracis: California, 2004. MMWR 2005 Apr 1;54(12):301-4 [Full text]
CDC. Inhalation anthrax associated with dried animal hides: Pennsylvania and New York City, 2006. MMWR 2006 Mar 17;55(10):280-2 [Full text]
CDC. Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR 2001;50(45):1014-6 [Full text]
CDC. Interim recommendations for firefighters and other first responders for the selection and use of protective clothing and respirators against biological agents [Full text]
CDC. Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 2001;50(41):889-93 [Full text]
CDC. Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR 2001;50(43);941-8 [Full text]
CDC. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR 2001;50(42)909-19 [Full text]
CDC. Investigation of bioterrorism-related inhalational anthrax--Connecticut, 2001. MMWR 2001;50(47):1049-51 [Full text]
CDC. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace. MMWR 2004 Jun 4;53(RR07):1-12 [Full text]
CDC. Surveillance for adverse events associated with anthrax vaccination?US Department of Defense, 1998-2000, MMWR 2000;49(16):341-5 [Full text]
CDC. Suspected cutaneous anthrax in a laboratory worker?Texas, 2002. MMWR 2002(Apr 5);51(13):279-81 [Full text]
CDC. Update on possible anthrax exposure in Department of Defense mail facility. From Health Alert Network. Mar 16, 2005 [Full text]
CDC. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR 2001;50(43):960 [Full text]
CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2002 Nov 15;51(45):1024-6 [Full text]
CDC. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR 2000;40(RR15):1-20 [Full text]
CDC. Use of ciprofloxacin or doxycycline for postexposure prophylaxis for prevention of inhalational anthrax (Health Advisory 10/31/01) [Full text]
CDC. Use of onsite technologies for rapidly assessing environmental Bacillus anthracis contamination on surfaces in buildings. MMWR 2001;50(48):1087 [Full text]
CDC/ASM/APHL. Basic diagnostic testing protocols for level A laboratories for the presumptive identification of Bacillus anthracis. Mar 18, 2002 [Full text]
CDER (Center for Drug Evaluation and Research). How to prepare emergency dosages of doxycycline at home for infants and children. Apr 25, 2003 [Full text]
Chakrabarty K, Wu W, Booth JL, et al. Human lung innate immune response to Bacillus anthracis spore infection. Infect Immun 2007 Aug;75(8):3729-38 [Abstract]
Chess C, Calis J, O'Neill KM. Communication triage: an anthrax case study. Biosecur Bioterr 2004;2(2):106
Chess C, Clarke L. Facilitation of risk communication during the anthrax attacks of 2001: the organizational backstory. Am J Public Health 2007 Sep 1;97(9):1578-83 [Abstract]
Chichester JA, Musiychuk K, de la Rosa P, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007 Apr 20;25(16):3111-4 [Abstract]
Chitlaru T, Gat O, Grosfeld H, et al. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome. Infect Immun 2007 Jun;75(6):2841-52 [Abstract]
Clarke TL, Rotarius T, Liberman A, et al. Responding to a bioterrorism attack - one scenario: part 1. Health Care Manag (Frederick) 2008 Jul/Sep;27(3):192-211 [Abstract]
Coker PR, Smith KL, Fellows PF, et al. Bacillus anthracis virulence in guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. J Clin Microbiol 2003 Mar;41(3):1212-8 [Abstract]
Coker PR, Smith KL, Hugh-Jones ME. Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002 Dec;46(12):3843-5 [Full text]
Coleman ME, Thran B, Morse SS, et al. Inhalation anthrax: dose response and risk analysis. Biosecur Bioterror 2008 Jun;6(2):147-60 [Abstract]
Comer JE, Chopra AK, Peterson JW, et al. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 2005 Dec;73(12):8275-81 [Abstract]
Cowan GJ, Atkins HS, Johnson LK, et al. Immunisation with anthrolysin O or a genetic toxoid protects against challenge with the toxin but not against Bacillus anthracis. Vaccine 2007 Oct 10;25(41):7197-205 [Abstract]
Cui X, Li Y, Laird MW, et al. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J Infect Dis 2007 Feb 15;195(4):572-80 [Abstract]
Cullamar EK, Lutwick LI. Inhalational anthrax. Curr Infect Dis Rep 2002 Jun;4(3):238-43 [Abstract]
Cunha BA. Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room. Clin Microbiol Rev 2002 Aug 8(8):489-503 [Abstract]
Cymet TC, Kerkvliet GJ, Tan JH, et al. Symptoms associated with anthrax exposure: suspected 'aborted' anthrax. J Am Osteopathic Assoc 2002;102(1):41-3 [Full text]
Dang O, Navarro L, Anderson K, et al. Anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J Immunol 2004 Jan 15;172:747-51 [Abstract]
Dauphin LA, Newton BR, Rasmussen MV, et al. Gamma irradiation can be used to inactivate Bacillus anthracis spores without compromising the sensitivity of diagnostic assays. Appl Environ Microbiol 2008 Jul;74(14):4427-33 [Abstract]
De BK, Bragg SSL, Sanden GN, et al. A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002 Oct;8(10):1060-5 [Full text]
Dewan PK, Fry AM, Laserson K, et al. Inhalational anthrax outbreak among postal workers, Washington, DC, 2001. Emerg Infect Dis 2002 Oct;8(10):1066-72 [Full text]
Dib EG, Dib SA, Korkmaz DA, et al. Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis. Emerg Infect Dis 2003 Aug;9(8):1013-5 [Full text]
Doganay M, Almac A, Hanagasi R. Primary throat anthrax: a report of six cases. Scand J Infect Dis 1986;18:415-9 [Abstract]
Doolan DL, Freilich DA, Brice GT, et al. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007 Jan 15;195(2):174-84 [Full text]
Drusano GL, Okusanya OO, Okusanya A, et al. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrob Agents Chemother 2008 Nov;52(11):3973-9 [Abstract]
Drysdale M, Olson G, Koehler TM, et al. Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains. Infect Immun 2007 Apr;75(4):1757-64 [Abstract]
DuBois AB, Freytag LC, Clements JD. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 2007 Jun 11;25(24):4747-54 [Abstract]
Dull PM, Wilson KE, Kournikakis B, et al. Bacillus anthracis aerosolization associated with a contaminated mail sorting machine. Emerg Infect Dis 2002 Oct;8(10):1044-7 [Full text]
Enstone JE, Wale MC, Nguyen-Van-Tam JS, et al. Adverse medical events in British service personnel following anthrax vaccination. Vaccine 2003 Mar 28;21(13-14):1348-54 [Abstract]
Erickson MC, Kornacki JL. Bacillus anthracis: current knowledge in relation to contamination of food. J Food Prot 2003 Apr;66(4):691-9 [Abstract]
Fasanella A, Losito S, Adone R, et al. PCR assay to detect Bacillus anthracis spores in heat-treated specimens. J Clin Microbiol 2003 Feb;41(2):896-9 [Abstract]
Fasanella A, Palazzo L, Petrella A, et al. Anthrax in red deer (Cervus elaphus), Italy. (Letter) Emerg Infect Dis 2007 Jul;13(7) (published online May 22) [Full text]
FDA. Authorization of emergency use of anthrax vaccine. Issued Jan 31, 2005 [Web page]
FDA. FDA clears lab culture test for anthrax. (Test is Redline Alert) Dec 9, 2003 [Full text]
FDA. FDA issues final rule and final order regarding safety and efficacy of certain licensed biological products including anthrax vaccine. Dec 30, 2003 [Full text]
Fennelly KP, Davidow AL, Miller SL, et al. Airborne infection with Bacillus anthracis--from mills to mail. (Perspective) Emerg Infect Dis 2004 Jun;10(6):996-1001 [Full text]
Fine AM, Wong JB, Fraser HS, et al. Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. Ann Emerg Med 2004 Mar;43(3):318-28 [Abstract]
Forino M, Johnson S, Wong TY, et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci 2005 (published online Jun 27) [Abstract]
Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of definding against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med 2005 Apr 19;142(8):601-10 [Abstract]
Fox A, Stewart GC, Waler LN, et al. Carbohydrates and glycoproteins of Bacillus anthracis and related bacilli: targets for biodetection. J Microbiol Methods 2003 Aug;54(2):143-52 [Abstract]
Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999;282(22):2104-6 [Abstract]
Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993 May;167(5):1239-43 [Abstract]
Friedlander AM. Anthrax. In: Zajtchuk R, Bellamy RF, eds. Textbook of military medicine: medical aspects of chemical and biological warfare. Chap 22. Washington, DC: Office of the Surgeon General, Borden Institute, Walter Reed Army Medical Center. [Full text]
Friedlander AM. Clinical aspects, diagnosis, and treatment of anthrax. J Appl Microbiol 1999;87:303 [Abstract]
Galen JE, Chinchilla M, Pasetti MF, et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2008 (published online Dec 19) [Abstract]
GAO (General Accounting Office) Better guidance is needed to improve communication should anthrax contamination occur in the future. GAO-03-316. Apr 2003 [Full text]
GAO (General Accounting Office). Public health response to anthrax incidents of 2001. Report to the Honorable Bill Frist, majority leader, U.S. Senate. GAO-04-152. Oct 15, 2003 [Full text]
GAO (Government Accountability Office). U.S. Postal Service: Better guidance is needed to ensure an appropriate response to anthrax contamination. GAO-04-239. Sep 2004 [Full text]
GAO (US Government Accountability Office). Project Bioshield: actions needed to avoid repeating past problems with procuring new anthrax vaccine and managing the stockpile of licensed vaccine. GAO-08-88. Oct 23, 2007 [Full text]
GAO. Anthrax detection: agencies need to validate sampling activities in order to increase confidence in negative results. GAO-05-493T. Apr 5, 2005 [Full text]
Gauthier YP, Tournier JN, Paucod JC, et al. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun 2008 (published online Dec 29) [Abstract]
Gerberding JL, Hughes JM, Koplan JP. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA (Editorial) 2002;287:898-900 [Full text]
Gierczynski R, Zasada AA, Raddadi N, et al. Specific Bacillus anthracis identification by a plcR-targeted restriction site insertion-PCR (RSI-PCR) assay. FEMS Microbiol Lett 2007 (published online May 8) [Abstract]
Gilsdorf JR. Jet-black eschar. Emerg Infect Dis 2002 Aug;8(8) [Full text]
Giorno R, Bozue J, Cote C, et al. Morphogenesis of the Bacillus anthracis spore. J Bacteriol 2007 Feb;189(3):691-705 [Abstract]
Glomski IJ, Piris-Gimenez A, Huerre M, et al. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog 2007 Jun 1;3(6):e76 [Full text]
Godyn JJ, Dotsey B. Prevalence of presumptive Bacillus anthracis in the human population examined by nasal swabs. Am J Infect Control 2004 Oct;32(6):355-7 [Abstract]
Gold H. Anthrax: A report of one hundred seventeen cases. Arch Intern Med 1955;96:387-96
Gold JA, Hoshino Y, Hoshino S, et al. Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect Immun 2004 Mar;72(3):1291-7 [Abstract]
Gold JA, Hoshino Y, Jones MB, et al. Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax. PLoS ONE 2007 Aug;2(8):e736 (published online Aug 15) [Full text]
Goldman DL, Zeng WY, Rivera J, et al. Human serum contains a protease that protects against cytotoxic activity of Bacillus anthracis lethal toxin in vitro. Clin Vaccine Immunol 2008 Jun;15(6):970-3 [Abstract]
Grabenstein JD. Countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008 Jan 1;46(1):129-36 [Full text]
Greene CM, Reefhuis J, Tan, C, et al. Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg Infect Dis 2002 Oct;8(10):1048-55 [Full text]
Griffith DS, Mead P, Armstrong GL, et al. Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001. Emerg Infect Dis 2003 Jun;9(6):681-8 [Full text]
Grunow R, Porsch-Ozcurumez M, Splettstoesser W, et al. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 2007 May 4;25(18):3679-83 [Abstract]
Gu M, Hine PM, Jackson WJ, et al. Increased potency of Biothrax(R) anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 2007 Jan 5;25(3):526-34 [Abstract]
Gubbins MJ, Schmidt L, Tsang RS, et al. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the US licensed anthrax vaccine. Immunoassay Immunochem 2007 Jul;28(3)213-25 [Abstract]
Gupta M, Alam S, Bhatnagar R. Catalytically inactive anthrax toxins(s) are potential prophylactic agents. Vaccine 2007 Dec 5;25(50):8410-9 [Abstract]
Gursky E, Inglesby TV, O'Toole T. Anthrax 2001: observations on the medical and public health response. Biosecurity Bioterrorism 2003;1(2):97-110 [Citation]
Hadjifrangiskou M, Chen Y, Koehler TM. The alternative sigma factor sigma H is required for toxin gene expression by Bacillus anthracis. J Bacteriol 2007 Mar;189(5):1874-83 [Abstract]
Hadler JL. Learning from the 2001 anthrax attacks: immunological characteristics. J Infect Dis 2007 Jan 15;195(2):163-4 [Full text]
Halverson KM, Panchal RG, Nguyen TL, et al. Anthrax biosensor: protective antigen ion channel asymmetric blockade. J Biol Chem 2005 (published online Aug 8) [Abstract]
Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998;225:13-3 [Abstract]
Hanson JF, Taft SC, Weiss AA. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 2006 Feb;13(2):208-13 [Abstract]
Hartley HA, Baeumner AJ. Biosensor for the specific detection of a single viable B anthracis sport. Anal Bioanal Chem 2003 Jun;376(3):319-27 [Abstract]
Hashimoto M, Boyer JL, Hackett NR, et al. Induction of protective immunity to anthrax lethal toxin with a nonhuman primar adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immunol 2005 Oct 1;73(10):6885-91 [Abstract]
Heine HS, Bassett J, Miller L, et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother 2008 Sep;52(9):3350-7 [Abstract]
Heller MB, Bunning ML, France MEB, et al. Laboratory response to anthrax bioterrorism, New York City, 2001. Emerg Infect Dis 2002 Oct;8(10):1096-1102 [Full text]
Heninger S, Drysdale M, Lovchik J, et al. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect Immun Nov;74(11):6067-74 [Abstract]
Hepburn MJ, Dyson EH, Simpson AJ, et al. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 2007 Aug 10;25(32):6089-97 [Abstract]
Hepler RW, Kelly R, McNeely TB, et al. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 2006 Mar 6;24(10):1501-14 [Abstract]
Hermanson G, Whitlow V, Parker S, et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci 2004 Sep 14;101(37):13601-6 [Abstract]
Higgins JA, Cooper M, Schroeder-Tucker L, et al. A field investigation of Bacillus anthracis contamination of US. Department of Agriculture and other Washington, DC, buildings during the anthrax attack of October 2001. [Abstract]
Hilgren J, Swanson KMJ, Diez-Gonzalez F, et al. Inactivation of Bacillus anthracis spores by liquid biocides in the presence of food residue. Appl Environ Microbiol 2007 Oct;73(20):6370-7 [Abstract]
Hoffmaster AR, Fitzgerald CC, Ribot E, et al. Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States. Emerg Infect Dis 2002 Oct;8(10):1111-6 [Full text]
Hoffmaster AR, Meyer RF, Bowen MD, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. (Letter) Emerg Infect Dis 2002 Oct;8(10):1078-82 [Full text]
Hoffmaster AR, Ravel J, Rasko DA, et al. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc Natl Acad Sci 2004 Jun 1;101(22):8449-54 [Full text]
Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006 Feb 21;144(4):270-80 [Abstract]
Holtz TH, Ackelsberg J, Kool JL, et al. Isolated case of bioterrorism-related inhalational anthrax, New York City, 2001. Emerg Infect Dis 2003 Jun 9(6):689-96 [Full text]
Howell JM, Mayer TA, Hanfling D, et al. Screening for inhalational anthrax due to bioterrorism: evaluating proposed screening protocols. Clin Infect Dis 2004 Dec 15;39(12):1842-7 [Abstract]
Hsu VP, Lukacs SL, Handzel T, et al. Opening a Bacillus anthracis?containing envelope, Capitol Hill, Washington, DC: the public health response. Emerg Infect Dis 2002 Oct;8(10):1039-43 [Full text]
Hughes JM, Gerberding JL. Anthrax bioterrorism: lessons learned and future directions. Emerg Infect Dis 2002 Oct;8(10):1013-4 [Full text]
Hupert N, Bearman GML, Mushlin AI, et al. Accuracy of screening for inhalational anthrax after a bioterrosit attack. Ann Intern Med 2003 Sep 2;139(5 Pt 1):337-45 (See also Sox below) [Abstract]
Hupert N, Chege W, Bearman GML, et al. Antibiotics for anthrax: patient requests and physician prescribing practices during the 2001 New York City attacks. Arch Int Med 2004;164(18):2012-6 [Abstract]
Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers. Emerg Infect Dis 2002 Oct;8(10):1138-44 [Full text]
Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002 Oct;8(10):1019-28 [Full text]
Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7(6) [Full text]
Jiang G, Joshi SB, Peek LJ, et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006 Jan;95(1):80-96 [Abstract]
Jones MB, Blaser MJ. Detection of a luxS-signaling molecule in Bacillus anthracis. Infect Immun 2003 Jul;71(7):3914-9 [Abstract]
Juris SJ, Melnyk RA, Bolcome RE 3rd, et al. Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin. Infect Immun 2007 Oct;75(10):5052-8 [Abstract]
Kadanali A, Tasyaran MA, Kadanali S. Anthrax during pregnancy: case reports and review. Clin Infect Dis 2003 May 15;36(10):1343-6 [Full text]
Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. 2003 May;9(5):520-5 [Full text]
Kao LM, Bush K, Barnewall R, et al. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob Agents Chemother 2006 Nov;50(11):3535-42 [Abstract]
Karginov VA, Nestorovich EM, Schmidtmann F, et al. Inhibition of S aureus alpha-hemolysin and B anthracis lethal toxin by beta-cyclodextrin derivatives. Bioorg Med Chem 2007 Aug 15;15(16):5421-31 [Abstract]
Karpouzis A, Panopoulou M, Bazzano G, et al. Extensive cutaneous anthrax in an immunocompetent patient. Eur J Dermatol 2007 Sep-Oct;17(5):443-5 [Abstract]
Kaufmann AF, Pesik NT, Meltzer MI. Syndromic surveillance in bioterrorist attacks. (Commentary) Emerg Infect Dis 2005 Sep;11(9) [Full text]
Kedar GC, Brown-Driver V, Reyes DR, et al. Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis. Antimicrob Agents Chemother 2007 May;51(5):1708-18 [Abstract]
Kelly CD, O'Loughlin C, Gelder FB, et al. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines 2007 5(1):11 (published online Oct 22) [Abstract]
Kenney RT, Yu J, Guebre-Xabier M, et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 2004 Aug 15;190(4):774-82 [Abstract]
Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 2004 Jan;72(1):430-9 [Abstract]
Kolla RV, Chintalapati S, Sabet M, et al. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS ONE 2007 Oct 17;2(10):e1044 [Full text]
Koya V, Moayeri M, Leppla SH, et al. Plant-based vaccine: mice immunized wtih chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun 2005 Dec;73(12):8266-74 [Abstract]
Kozel TR, Thorkildson P, Brandt S, et al. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun 2007 Jan;75(1):152-63 [Abstract]
Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003 Feb 1;36(3):328-36 [Abstract]
Kumar P, Ahuja N, Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect Immun 2002 Sep;70(9):4997-5007 [Full text]
Kwok WW, Yang J, James E, et al. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Infect Immun 2008 Oct;76(10):4538-45 [Abstract]
Kyriacou D, Schmitt B, Dobrez D, et al. Cost-effectiveness analysis of time-varying response strategies to a large-scale bioterrorist anthrax attack. Acad Emerg Med 2007 May;14(5 suppl 1):S13 [Abstract]
Kyriacou DN, Stein AD, Yarnold P, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004 Jul 31;364(9432):449-52 [Abstract - See also Mogridge below]
Lanska DJ. Anthrax meningoencephalitis. Neurology 2002 Aug 13;59(3):327-34 [Abstract]
Lee JY, Janes BK, Passalacqua KD, et al. Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis. J Bacteriol 2007 Mar;189(5):1698-1710 [Abstract]
Lee YS, Bergson P, He WS, et al. Discovery of a small molecule that inhibits the interation of anthrax edema factor with its cellular activator, calmodulin. Chem Biol 2004 Aug;11(8):1139-46 [Abstract]
Leendertz FH, Ellerbrok H, Boesch C, et al. Anthrax kills wild chimpanzees in a tropical rain forest. (Letter) Nature 2004 Jul 22;430:481-2 [Full text]
Leffel EK, Twenhafel NA, Whitehouse CA. Nosocomial infection of Serratia marcescens may induce a protective effect in monkeys exposed to Bacillus anthracis. J Infect 2008 Aug;57(2):162-4 [Abstract]
Lemieux P, Sieber R, Osborne A, et al. Destruction of spores on building decontamination residue in a commercial autoclave. Appl Environ Microbiol 2006 Dec;72(12):7687-93 [Abstract]
Lester ED, Bearman G, Ponce A. A second-generation anthrax "smoke detector": an inexpensive front-end monitor that detects airborne bacterial spores. IEEE Eng Med Biol Mag 2004;23(1):130-5
Levin DB, Valadares De Amorim G. Potential for aerosol dissemination of biological weapons: lessons from biological control of insects. Biosec Bioterror 2003;1(1):37-42
Lininger LA, Cullum ME, Lyles MB, et al. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine. Vaccine 2007 Feb 19;25(9):1619-25 [Abstract]
Lisanby MW, Swiecki MK, Dizon BL, et al. Cathelicidin administration protects mice from Bacillus anthracis spore challenge. J Immunol 2008 Oct;181(7):4989-5000 [Abstract]
Little SF, Ivins BE, Webster WM, et al. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007 Apr 12;25(15):2771-7 [Abstract]
Liu H, Bergman NH, Thomason B, et al. Formation and composition of the Bacillus anthracis endospore. J Bacteriol 2004 Jan;186(1):164-78 [Abstract]
Loose C, Jensen K, Rigoutsos I, et al. A linguistic model for the rational design of antimcrobial peptides. Nature 2006 Oct 19;443(7113):867-9 [Abstract]
Louie A, Heine HS, Kim K, et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 2008 Jun;52(7):2486-96 [Abstract]
Luna VA, King D, Davis C, et al. Novel sample preparation method for safe and rapid detection of Bacillus anthracis spores in environmental powders and nasal swabs. J Clin Microbiol 2003 Mar;41(3):1252-5 [Abstract]
Luxembourg A, Hannaman D, Nolan E, et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008 Sep 26;26(41):5216-22 [Abstract]
Mabry R, Rani M, Geiger R, et al. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005 Dec;73(12):8362-8 [Abstract]
Manayani DJ, Thomas D, Dryden KA, et al. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog 2007 Oct 5;3(10):e142 [Full text]
Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months. JAMA 2008 Oct 1;300(13):1532-3 [Abstract]
Matyas GR, Friedlander AM, Glenn GM, et al. Needle-free skin patch vaccination method for anthrax. Infect Immun 2004 Feb;72(2):1181-3 [Abstract]
Mayer TA, Bersoff-Matcha S, Murphy C, et al Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients. JAMA 2001;286(20):2549-53 [Full text]
Mayer TA, Morrison A, Bersoff-Matcha S, et al. Inhalational anthrax due to bioterrorism: would current CDC guidelines have identified the 11 patients with inhalational anthrax from Oct through Nov 2001? Clin Infect Dis 2003 May 15;36(10):1275-83 [Full text]
Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002 Jun;20(6):597-601 [Abstract]
McKevitt MT, Bryant KM, Shakir SM, et al. Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections. Infect Immun 2007 Dec;75(12):5726-34 [Abstract]
McNeil MM, M G, Aranas A, et al. A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting System. Vaccine 2007 Apr 30;25(17):3428-36 [Abstract]
Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-8 [Abstract]
Meyer MA Neurologic complications of anthrax: a review of the literature. Arch Neurol 2003 Apr;60(4):483-8 [Abstract]
Meyerhoff A, Albrecht R, Meyer JM, et al. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis 2004 Aug 1;39(3):303-8 [Abstract]
Mikszata JA, Dekker JP 3rd, Harvey NG, et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infection Immun 2006 Dec;74(12):6806-10 [Abstract]
Mikszta JA, Sullivan VJ, Dean C, et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 2005 Jan 15;19(2):278-88 [Abstract]
Min DH, Tang WJ, Mrksich M. Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat Biotechnol 2004 Jun;22(6):717-23 [Abstract]
Mina B, Dym JP, Kuepper F, et al. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA 2002;287:858-62 [Full text]
Moayeri M, Haines D, Young HA, et al. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 2003 Sep;112(5):670-82 [Full text]
| 
